Newsroom | 57465 results

Sorted by: Latest

Research
-

Nomic Publishes Foundational Protein Quantification Technology in Nature Methods

MONTREAL--(BUSINESS WIRE)--Nomic Bio (“Nomic”) today announced publication of its core nELISA® technology in Nature Methods, detailing a high‑throughput, high‑plex immunoassay platform that side-steps reagent‑driven cross‑reactivity to maintain exquisite specificity at scale. Coinciding with the publication, Nomic unveiled a 1.4 million-data-point PBMC cytokine perturbation dataset in the Nomic Portal, an intuitive platform for exploring and analyzing proteomic data. The study describes the nov...
-

​​Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor...
-

CrossBridge Bio Wins “Best Drug Developer” at 2025 World ADC Awards

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biopharmaceutical company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer more durable responses in patients, including those resistant to approved ADC therapies, today announced that it has been named the Winner of “Best Drug Developer” at the 2025 World ADC Awards. CrossBridge Bio was selected from a competitive global field by a panel of independent ADC experts and peers. The award r...
-

New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today presented promising new Phase 2 data from its ongoing study of imneskibart in patients with checkpoint inhibitor (CPI)-refractory melanoma and non-small cell lung cancer (NSCLC). The data were shared in a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual M...
-

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida. Hypereosinophilic Syndrome (HES) is a group of...
-

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of STK-012 in first-line, PD-L1 negative nonsquamous (NSQ) non-small cell lung cancer (NSCLC) in combination with standard of care (SoC) pembrolizumab and chemotherapy (PCT). The data will be presented by Adam J. Schoenfeld, M.D., Memorial Sloan Kettering Cancer Center, New York, as a late-breaking oral presentation at the...
-

The Baxter Foundation Announces $2.6M Grant to Advance STEM Education in Chicagoland Through Partnership With Northwestern University

DEERFIELD, Ill.--(BUSINESS WIRE)--The Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the continuation of a partnership with Northwestern University’s School of Education and Social Policy (SESP) to provide science, technology, engineering and math (STEM) programs for students and teachers throughout the Chicagoland area. Supported by a three-year $2.6 million grant from the Foundation, the Baxter Center for Science Educ...
-

Resumen: Scientist.com gana el premio B2B Ecommerce Awards a la excelencia en la gestión de proveedores

SAN DIEGO--(BUSINESS WIRE)--Scientist.com, la plataforma líder de coordinación de I+D con IA para las ciencias de la vida, ha sido galardonada con el premio a la excelencia en la gestión de los proveedores por los prestigiosos premios B2B Ecommerce Awards. Se trata de un galardón que reconoce a las organizaciones que sientan nuevos parámetros en materia de innovación, integración y rendimiento de la red de proveedores para ofrecerle un valor superior al cliente. "Haber ganado este premio es un...
-

Scientist.com remporte le premier prix dans la catégorie « Excellence en gestion des fournisseurs » lors des B2B Ecommerce Awards

SAN DIEGO--(BUSINESS WIRE)--Scientist.com, la principale plateforme d’orchestration de la R&D basée sur l’IA pour le secteur des sciences de la vie, a reçu le premier prix dans la catégorie « Excellence en gestion des fournisseurs » lors des prestigieux B2B Ecommerce Awards. Ce prix récompense les organisations qui fixent de nouvelles normes en matière d’innovation, d’intégration et de performance dans le cadre de leur réseau de fournisseurs afin d’offrir une valeur ajoutée supérieure à leu...
-

Riassunto: Scientist.com si aggiudica il premio per la Supplier Management Excellence ai B2B Ecommerce Awards

SAN DIEGO--(BUSINESS WIRE)--Scientist.com, piattaforma AI leader nell'orchestrazione R&D per il comparto delle scienze della vita, è la vincitrice del premio Supplier Management Excellence assegnato dai prestigiosi B2B Ecommerce Awards. Il riconoscimento è rivolto alle organizzazioni che creano nuovi standard nell'innovazione, nell'integrazione e nelle performance della rete di fornitori per offrire ai clienti un valore aggiunto di livello superiore. "Vincere questo premio rappresenta un on...